In a significant move towards advancing the field of antibody therapeutics, Takeda and F-star Therapeutics have announced a strategic collaboration focused on the development of next-generation multi-specific antibodies. The collaboration, that could be worth up to US$1.0 B, will leverage F-star’s proprietary fully-human Fcab™ and tetravalent mAb²™ platforms to research and develop multi-specific immunotherapies for undisclosed cancer indications. This latest collaboration between Takeda and F-star Therapeutics marks their third partnership of its kind.